Literature DB >> 18060547

Whole body [11C]-dihydrotetrabenazine imaging of baboons: biodistribution and human radiation dosimetry estimates.

Rajan Murthy1, Paul Harris, Norman Simpson, Ronald Van Heertum, Rudolph Leibel, J John Mann, Ramin Parsey.   

Abstract

PURPOSE: Vesicular monoamine transporter type 2 abundance quantified using the radiotracer [(11)C]-dihydrotetrabenazine (DTBZ) has been used to study diagnosis and pathogenesis of dementia and psychiatric disorders in humans. In addition, it may be a surrogate marker for insulin-producing pancreatic beta cell mass, useful for longitudinal measurements using positron emission tomography to track progression of autoimmune diabetes. To support the feasibility of long-term repeated administrations, we estimate the biodistribution and dosimetry of [(11)C]-DTBZ in humans.
METHODS: Five baboon studies were acquired using a Siemens ECAT camera. After transmission scanning, 165-210 MBq of [(11)C]-DTBZ were injected, and dynamic whole body emission scans were conducted. Time-activity data were used to obtain residence times and estimate absorbed radiation dose according to the MIRD model.
RESULTS: Most of the injected tracer localized to the liver and the lungs, followed by the intestines, brain, and kidneys. The highest estimated absorbed radiation dose was in the stomach wall.
CONCLUSIONS: The largest radiation dose from [(11)C]-DTBZ is to the stomach wall. This dose estimate, as well as the radiation dose to other radiosensitive organs, must be considered in evaluating the risks of multiple administrations.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18060547     DOI: 10.1007/s00259-007-0648-2

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  34 in total

1.  A comparison of tetrabenazine and chlorpromazine in chronic schizophrenia.

Authors:  G W ASHCROFT; E J MACDOUGALL; P A BARKER
Journal:  J Ment Sci       Date:  1961-03

2.  Vesicular monoamine transporter concentrations in bipolar disorder type I, schizophrenia, and healthy subjects.

Authors:  J K Zubieta; S F Taylor; P Huguelet; R A Koeppe; M R Kilbourn; K A Frey
Journal:  Biol Psychiatry       Date:  2001-01-15       Impact factor: 13.382

3.  Characterization of [11C]tetrabenazine as an in vivo radioligand for the vesicular monoamine transporter.

Authors:  J N DaSilva; J E Carey; P S Sherman; T J Pisani; M R Kilbourn
Journal:  Nucl Med Biol       Date:  1994-02       Impact factor: 2.408

4.  Effects of tryptophan depletion on the binding of [11C]-DASB to the serotonin transporter in baboons: response to acute serotonin deficiency.

Authors:  Matthew S Milak; R Todd Ogden; Daniel N Vinocur; Ronald L Van Heertum; Thomas B Cooper; J John Mann; Ramin V Parsey
Journal:  Biol Psychiatry       Date:  2005-01-01       Impact factor: 13.382

5.  Biodistribution and radiation dosimetry of [11C]DASB in baboons.

Authors:  Marie-José Bélanger; Norman R Simpson; Theodore Wang; Ronald L Van Heertum; J John Mann; Ramin V Parsey
Journal:  Nucl Med Biol       Date:  2004-11       Impact factor: 2.408

6.  Differential trafficking of the vesicular monoamine transporter-2 by methamphetamine and cocaine.

Authors:  Evan L Riddle; Matthew K Topham; John W Haycock; Glen R Hanson; Annette E Fleckenstein
Journal:  Eur J Pharmacol       Date:  2002-08-02       Impact factor: 4.432

7.  Methylphenidate redistributes vesicular monoamine transporter-2: role of dopamine receptors.

Authors:  Verónica Sandoval; Evan L Riddle; Glen R Hanson; Annette E Fleckenstein
Journal:  J Neurosci       Date:  2002-10-01       Impact factor: 6.167

8.  Monoamine vesicular uptake sites in patients with Parkinson's disease and Alzheimer's disease, as measured by tritiated dihydrotetrabenazine autoradiography.

Authors:  S Lehéricy; J P Brandel; E C Hirsch; P Anglade; J Villares; D Scherman; C Duyckaerts; F Javoy-Agid; Y Agid
Journal:  Brain Res       Date:  1994-10-03       Impact factor: 3.252

9.  Localization of vesicular monoamine transporter isoforms (VMAT1 and VMAT2) to endocrine cells and neurons in rat.

Authors:  E Weihe; M K Schäfer; J D Erickson; L E Eiden
Journal:  J Mol Neurosci       Date:  1994       Impact factor: 3.444

10.  Synthesis of a [11C]methoxy derivative of alpha-dihydrotetrabenazine: a radioligand for studying the vesicular monoamine transporter.

Authors:  J N DaSilva; M R Kilbourn; T J Mangner
Journal:  Appl Radiat Isot       Date:  1993-12       Impact factor: 1.513

View more
  12 in total

Review 1.  Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes.

Authors:  Chris de Graaf; Dan Donnelly; Denise Wootten; Jesper Lau; Patrick M Sexton; Laurence J Miller; Jung-Mo Ahn; Jiayu Liao; Madeleine M Fletcher; Dehua Yang; Alastair J H Brown; Caihong Zhou; Jiejie Deng; Ming-Wei Wang
Journal:  Pharmacol Rev       Date:  2016-10       Impact factor: 25.468

Review 2.  In vivo beta-cell imaging with VMAT 2 ligands--current state-of-the-art and future perspective.

Authors:  Rajakrishnan Veluthakal; Paul Harris
Journal:  Curr Pharm Des       Date:  2010-05       Impact factor: 3.116

3.  Study of Vesicular Monoamine Transporter 2 in Myopic Retina Using [18F]FP-(+)-DTBZ.

Authors:  Yu Sun; Ning Zhao; Wangyuan Liu; Miao Liu; Zizhao Ju; Jun Li; Zhen Cheng; Xingdang Liu
Journal:  Mol Imaging Biol       Date:  2018-10       Impact factor: 3.488

4.  A genomic-based approach identifies FXYD domain containing ion transport regulator 2 (FXYD2)gammaa as a pancreatic beta cell-specific biomarker.

Authors:  D Flamez; I Roland; A Berton; B Kutlu; D Dufrane; M C Beckers; E De Waele; I Rooman; L Bouwens; A Clark; M Lonneux; J F Jamar; S Goldman; D Maréchal; N Goodman; P Gianello; C Van Huffel; I Salmon; D L Eizirik
Journal:  Diabetologia       Date:  2010-04-09       Impact factor: 10.122

5.  Ex vivo imaging of pancreatic beta cells using a radiolabeled GLP-1 receptor agonist.

Authors:  Brett M Connolly; Amy Vanko; Paul McQuade; Ilonka Guenther; Xiangjun Meng; Daniel Rubins; Rikki Waterhouse; Richard Hargreaves; Cyrille Sur; Eric Hostetler
Journal:  Mol Imaging Biol       Date:  2012-02       Impact factor: 3.488

Review 6.  Vesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistry.

Authors:  Kandatege Wimalasena
Journal:  Med Res Rev       Date:  2010-02-04       Impact factor: 12.944

Review 7.  Advances in beta-cell imaging.

Authors:  Anna Moore
Journal:  Eur J Radiol       Date:  2009-03-03       Impact factor: 3.528

8.  Novel hypoglycemic dihydropyridones serendipitously discovered from O- versus C-alkylation in the synthesis of VMAT2 antagonists.

Authors:  Yuli Xie; Anthony Raffo; Masanori Ichise; Shixian Deng; Paul E Harris; Donald W Landry
Journal:  Bioorg Med Chem Lett       Date:  2008-08-07       Impact factor: 2.823

9.  Glucagon-like peptide-1 (GLP-1) analogs: recent advances, new possibilities, and therapeutic implications.

Authors:  Bikash Manandhar; Jung-Mo Ahn
Journal:  J Med Chem       Date:  2014-11-13       Impact factor: 7.446

10.  Radiomanganese PET Detects Changes in Functional β-Cell Mass in Mouse Models of Diabetes.

Authors:  Reinier Hernandez; Stephen A Graves; Trillian Gregg; Halena R VanDeusen; Rachel J Fenske; Haley N Wienkes; Christopher G England; Hector F Valdovinos; Justin J Jeffery; Todd E Barnhart; Gregory W Severin; Robert J Nickles; Michelle E Kimple; Matthew J Merrins; Weibo Cai
Journal:  Diabetes       Date:  2017-05-17       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.